



**S4 Fig. Risk of primary safety outcome in subgroups** Hazard ratios (HR) and 95% confidence intervals (CI) adjusted for sex, age and comorbidities for the risk of major or clinically relevant non-major bleeding in subgroups of new users of warfarin, dabigatran, rivaroxaban or apixaban for non-valvular atrial fibrillation. The comparator is dabigatran in the high- and low-intensity DOAC subgroups, otherwise warfarin. Norway, 15 July 2013 to 31 December 2015. ASA, acetylsalicylic acid.